Caris Life Sciences (CAI) Director Jeff Vacirca Receives Award

What Happened
Jeff L. Vacirca, a director of Caris Life Sciences, was granted 13,192 restricted stock units (RSUs) on August 14, 2026. The Form 4 shows an award/acquisition (code A) at $0.00 per share — the grant required no cash outlay at issuance. This is a compensation award (not a market purchase or sale) that will convert to shares if and when the RSUs vest under the grant terms.

Key Details

• Transaction date: 2026-08-14 (filed same day).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 13,192 RSUs. Price per unit reported: $0.00; total cash paid: $0.
• Shares owned after transaction: Not reported on this Form 4.
• Footnote: F1 — The award represents restricted stock units that will vest in accordance with the applicable grant agreement.
• Timeliness: Filing date matches transaction date (no late filing indicated).

Context
RSUs are a form of equity compensation that give the holder a right to receive shares (or cash equivalent) in the future after meeting vesting conditions (time-based, performance-based, or both). Grants are routine for company directors and executives as part of compensation packages and do not by themselves indicate buying or selling sentiment. Taxable income and actual share ownership will generally occur when RSUs vest and are settled.